OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
| Autor: | Luis E. Pablo, Silvia Mendez-Martinez, Jesús Leciñena Bueno, Pilar Calvo, Nieves Pardiñas Barón, María Del Rocío Gil Ruiz, Oscar Ruiz-Moreno |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Mitogen-Activated Protein Kinase Kinases
MAPK/ERK pathway Oncology medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions business.industry MEDLINE General Medicine 03 medical and health sciences Ophthalmology 0302 clinical medicine Text mining Retinal Diseases 030220 oncology & carcinogenesis Internal medicine Cutaneous melanoma 030221 ophthalmology & optometry medicine Humans business Adverse effect Protein kinase A Protein Kinase Inhibitors neoplasms |
| Zdroj: | Retina. 39:1435-1450 |
| ISSN: | 0275-004X |
| DOI: | 10.1097/iae.0000000000002451 |
| Popis: | Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors, have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; however, oncologists, ophthalmologists, and patients have noticed different toxicities of variable importance. This review aims to provide an update of the ocular adverse events (OAEs), especially retinal toxicity, associated with the use of MEK inhibitors.We conducted a scientific literature search using the PubMed database up to July 2018 with the terms "MEK inhibitors" with a "review" filter and "MEK inhibitors" with a "clinical trials" filter. Phase I-III experimental studies and reviews were selected. Current principles and techniques for diagnosing and managing MEK inhibitor retinopathy and other OAEs are discussed.In patients treated with MEK inhibitors, including asymptomatic patients, OAEs occur with an incidence of up to 90%. Mild to severe ophthalmic toxicities are described, including visual disturbances, a 2-line decrease in Snellen visual acuity, dry eye symptoms, ocular adnexal abnormalities, visual field defects, panuveitis, and retinal toxicities, such as different degrees of MEK-associated retinopathy, vascular injury, and retinal vein occlusion.MEK inhibitors can lead to different degrees of retinal, uveal, and adnexal OAE, causing visual disturbances or discomfort. One of the most relevant OAE of MEK therapy is MEK inhibitor-associated retinopathy (MEKAR), which is usually mild, self-limited, and may subside after continuous use of the drug for weeks or months, or discontinuation, thereby restoring the normal visual function of the retina, with some exceptions. Ocular adverse events are often associated with other systemic adverse effects that can modify the dosage of treatment, so the communication with the oncologist is fundamental. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|